BRSYF Stock News 15.6200 05/06/2014 15:29:12 Brainsway Ltd (
Post# of 273328
Posted On: 05/06/2014 4:29:03 PM
Brainsway Ltd (BRSYF) 15.6200 $BRSYF
Best's Rating Notification - Reaseguradora America SPC Ltd.
Rating Division - AMBest - Thu Jan 16, 3:00PM CST
A.M. Best Company has made the following rating update:
Brainsway Receives FDA Approval of IDE for Obsessive-Compulsive Disorder Study
GlobeNewswire - Thu Dec 19, 7:32AM CST
Brainsway Ltd. (TASE:BRIN) is pleased to announce that the U.S. Food and Drug Administration ("FDA"
has approved an Investigational Device Exemption ("IDE" that allows the Company to begin implementing a double-blind, multi-center study to assess the efficacy of the its Deep TMS device in treating patients suffering from obsessive-compulsive disorder ("OCD".
Cameron Associates Initiates Coverage of Brainsway, Ltd.
PR Newswire Europe - Fri Dec 13, 2:22AM CST
-- Brainsway Pioneers Novel Treatment for Broad Range of Brain Disorders
Brainsway Receives FDA Approval of IDE for Multi-Center Smoking Cessation Study
GlobeNewswire - Wed Sep 11, 12:30PM CDT
Brainsway Ltd. (TASE:BRIN) is pleased to announce that the U.S. Food and Drug Administration ("FDA" has approved an IDE ("Investigational Device Exemption" that allows the Company to begin implementing a double-blind, multi-center study to assess the efficacy of the its Deep TMS device in inducing smoking cessation using a specialized coil developed for this purpose.
Brainsway Reports Positive Final Results of Study Using Deep TMS to Treat OCD
GlobeNewswire - Wed Sep 04, 6:48AM CDT
Brainsway Ltd. (TASE:BRIN) is pleased to report the final results of a clinical trial conducted at the Sheba Medical Center at Tel Hashomer to assess the efficacy of the Company's Deep TMS device in treating obsessive-compulsive disorder ("OCD" using a specialized coil developed for this purpose.
Brainsway Provides Commercialization Progress Update
GlobeNewswire - Mon Jul 22, 3:01PM CDT
Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company" announced today that, further to its press release of May 1, 2013, there are now approximately 50 Deep TMS systems in various stages of installation, implementation and customer training. Brainsway also advised that, based on the current number of new system orders outstanding and the continuing strong interest shown by psychiatrists, clinics and medical centers, the Company estimates that it will complete the installation and customer implementation of approximately 100 Deep TMS systems for commercial use by the end of 2013.
Brainsway Poised for Commercial Launch of Deep TMS in the United States
GlobeNewswire - Wed May 01, 7:30AM CDT
Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company" is proud to announce that, after completing production of approximately 100 Deep TMS systems, it intends to initiate U.S. commercial sales of the device within the next few days. In addition, Brainsway has slated the official U.S. marketing launch of Deep TMS for the American Psychiatric Association ("APA" 2013 Annual Meeting to be held May 18-22 in San Francisco, CA.
Brainsway Announces Final Results in Clinical Trial for Smoking Cessation in Chronic Obstructive Pulmonary Disease Patients
GlobeNewswire - Thu Jan 24, 2:54PM CST
Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company) is pleased to announce that it has received final results with respect to a clinical trial that was conducted at the Be'er Ya'akov Mental Health Center to assess the efficacy of the Company's Deep TMS device in inducing smoking cessation in chronic obstructive pulmonary disease ("COPD" patients using a specialized coil developed for this purpose.
Brainsway Receives FDA Approval
GlobeNewswire - Thu Jan 10, 11:14AM CST
Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company" is proud to announce that the U.S. Food and Drug Administration ("FDA" has approved its proprietary Deep TMS device for the treatment of depression in patients who have failed to respond to antidepressant medications in their current episode of depression. It should be noted that this indication for the use of Brainsway's device, as approved by the FDA, is broad, both in general terms as it relates to depression therapy and compared to the FDA-approved indications for the use of competing TMS therapy.
Best's Rating Notification - Reaseguradora America SPC Ltd.
Rating Division - AMBest - Thu Jan 16, 3:00PM CST
A.M. Best Company has made the following rating update:
Brainsway Receives FDA Approval of IDE for Obsessive-Compulsive Disorder Study
GlobeNewswire - Thu Dec 19, 7:32AM CST
Brainsway Ltd. (TASE:BRIN) is pleased to announce that the U.S. Food and Drug Administration ("FDA"
has approved an Investigational Device Exemption ("IDE" that allows the Company to begin implementing a double-blind, multi-center study to assess the efficacy of the its Deep TMS device in treating patients suffering from obsessive-compulsive disorder ("OCD". Cameron Associates Initiates Coverage of Brainsway, Ltd.
PR Newswire Europe - Fri Dec 13, 2:22AM CST
-- Brainsway Pioneers Novel Treatment for Broad Range of Brain Disorders
Brainsway Receives FDA Approval of IDE for Multi-Center Smoking Cessation Study
GlobeNewswire - Wed Sep 11, 12:30PM CDT
Brainsway Ltd. (TASE:BRIN) is pleased to announce that the U.S. Food and Drug Administration ("FDA"
has approved an IDE ("Investigational Device Exemption" that allows the Company to begin implementing a double-blind, multi-center study to assess the efficacy of the its Deep TMS device in inducing smoking cessation using a specialized coil developed for this purpose. Brainsway Reports Positive Final Results of Study Using Deep TMS to Treat OCD
GlobeNewswire - Wed Sep 04, 6:48AM CDT
Brainsway Ltd. (TASE:BRIN) is pleased to report the final results of a clinical trial conducted at the Sheba Medical Center at Tel Hashomer to assess the efficacy of the Company's Deep TMS device in treating obsessive-compulsive disorder ("OCD"
using a specialized coil developed for this purpose. Brainsway Provides Commercialization Progress Update
GlobeNewswire - Mon Jul 22, 3:01PM CDT
Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company"
announced today that, further to its press release of May 1, 2013, there are now approximately 50 Deep TMS systems in various stages of installation, implementation and customer training. Brainsway also advised that, based on the current number of new system orders outstanding and the continuing strong interest shown by psychiatrists, clinics and medical centers, the Company estimates that it will complete the installation and customer implementation of approximately 100 Deep TMS systems for commercial use by the end of 2013. Brainsway Poised for Commercial Launch of Deep TMS in the United States
GlobeNewswire - Wed May 01, 7:30AM CDT
Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company"
is proud to announce that, after completing production of approximately 100 Deep TMS systems, it intends to initiate U.S. commercial sales of the device within the next few days. In addition, Brainsway has slated the official U.S. marketing launch of Deep TMS for the American Psychiatric Association ("APA" 2013 Annual Meeting to be held May 18-22 in San Francisco, CA. Brainsway Announces Final Results in Clinical Trial for Smoking Cessation in Chronic Obstructive Pulmonary Disease Patients
GlobeNewswire - Thu Jan 24, 2:54PM CST
Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company) is pleased to announce that it has received final results with respect to a clinical trial that was conducted at the Be'er Ya'akov Mental Health Center to assess the efficacy of the Company's Deep TMS device in inducing smoking cessation in chronic obstructive pulmonary disease ("COPD"
patients using a specialized coil developed for this purpose. Brainsway Receives FDA Approval
GlobeNewswire - Thu Jan 10, 11:14AM CST
Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company"
is proud to announce that the U.S. Food and Drug Administration ("FDA" has approved its proprietary Deep TMS device for the treatment of depression in patients who have failed to respond to antidepressant medications in their current episode of depression. It should be noted that this indication for the use of Brainsway's device, as approved by the FDA, is broad, both in general terms as it relates to depression therapy and compared to the FDA-approved indications for the use of competing TMS therapy. 
(0)
(0)